Related Experiment Video
Updated: Aug 14, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Drug-induced refractory arterial hypertension]
E Frangos Lordos1, V Trombert, I Kuzmanovic
1Service de médecine interne générale, Genève. emilia.frangos@hcuge.ch
Revue Medicale Suisse
|December 6, 2005
Summary
Drug interactions are common in elderly patients. Carbamazepine can reduce the effectiveness of blood pressure medications, highlighting the need for careful drug review in polymedicated individuals.
Area of Science:
- Geriatric Medicine
- Clinical Pharmacology
- Drug Interactions
Background:
- Polymedication is prevalent in elderly patients, increasing the risk of adverse drug events.
- Drug-drug interactions (DDIs) can lead to therapeutic ineffectiveness or toxicity.
- Physicians must remain vigilant for potential DDIs in geriatric care.
Observation:
- A patient presented with refractory arterial hypertension despite a five-drug antihypertensive regimen.
- The patient was concurrently taking carbamazepine for facial neuralgia.
- Carbamazepine is known to induce cytochrome P450 enzymes, affecting drug metabolism.
Findings:
- Carbamazepine-induced cytochrome P450 enzyme activity likely accelerated the metabolism of multiple antihypertensive medications.
- Discontinuation of carbamazepine led to improved blood pressure control.
- A simplified tritherapy regimen became effective after carbamazepine withdrawal.
Implications:
- This case underscores the critical importance of considering drug-drug interactions in cases of unexpected therapeutic failure.
- Comprehensive medication reviews are essential for elderly patients, especially those on multiple medications.
- Awareness of enzyme-inducing drugs like carbamazepine is crucial for managing hypertension in polymedicated individuals.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...